AstraZeneca plans a $50bn investment in US manufacturing and R&D by 2030, responding to Trump’s tariff threats and signalling a strategic pivot toward its largest market.

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing and research and development (R&D).

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump administration claiming some credit due to its tariff policy and

The biopharmaceutical company AstraZeneca announced it will $50 billion into the United States, with plans to open several manufacturing facilities in several states.

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence in the company's largest market.

The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.

AstraZeneca has increased its investment in U.S. operations more than 14-fold, committing $50 billion to a range of manufacturing and R&D projects planned over the next five years.

The company said the Virginia facility "would be AstraZeneca’s largest single manufacturing investment in the world." The proposed site was not disclosed.

AstraZeneca opened its global headquarters and research and discovery centre at the £1billion Discovery Centre (the DISC) on the campus in 2021. And at the start of 2025, it began construction on its new office building, the Rosalind Franklin Building, on the other side of Francis Crick Avenue.